Drug Profile
Research programme: neurodegenerative disorder therapeutics - Kadimastem/Merck Serono
Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Kadimastem; Merck Serono
- Class
- Mechanism of Action Glial cell modulators; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis; Neurodegenerative disorders
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Neurodegenerative-disorders in Israel (PO)
- 28 Jul 2018 No recent reports of development identified for research development in Multiple-sclerosis in Israel (PO)
- 29 Sep 2015 Kadimastem receives grant from the National Multiple Sclerosis Society for the development in nerve-insulating myelin in Multiple sclerosis